BR9911115A - Composições farmacêuticas e usos para oandrost-5-eno-3 beta, 17 beta-diol - Google Patents

Composições farmacêuticas e usos para oandrost-5-eno-3 beta, 17 beta-diol

Info

Publication number
BR9911115A
BR9911115A BR9911115-2A BR9911115A BR9911115A BR 9911115 A BR9911115 A BR 9911115A BR 9911115 A BR9911115 A BR 9911115A BR 9911115 A BR9911115 A BR 9911115A
Authority
BR
Brazil
Prior art keywords
beta
oandrost
diol
pharmaceutical compositions
ene
Prior art date
Application number
BR9911115-2A
Other languages
English (en)
Portuguese (pt)
Inventor
Fernand Labrie
Original Assignee
Endorech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endorech Inc filed Critical Endorech Inc
Publication of BR9911115A publication Critical patent/BR9911115A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR9911115-2A 1998-06-11 1999-06-10 Composições farmacêuticas e usos para oandrost-5-eno-3 beta, 17 beta-diol BR9911115A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9628698A 1998-06-11 1998-06-11
PCT/CA1999/000537 WO1999063973A2 (en) 1998-06-11 1999-06-10 PHARMACEUTICAL COMPOSITIONS AND USES FOR ANDROST-5-ENE-3β,17β-DIOL

Publications (1)

Publication Number Publication Date
BR9911115A true BR9911115A (pt) 2001-12-04

Family

ID=22256669

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9911115-2A BR9911115A (pt) 1998-06-11 1999-06-10 Composições farmacêuticas e usos para oandrost-5-eno-3 beta, 17 beta-diol

Country Status (22)

Country Link
US (12) US6432940B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (2) EP1083904A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP2002517432A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (3) KR100679735B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (3) CN1879630A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (1) AR018660A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU4127499A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR9911115A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2334702C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HUP0102483A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ID (1) ID27922A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (2) IL140225A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MXPA00012304A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MY (1) MY131522A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO20006286L (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ536787A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL345955A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2221569C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TR (2) TR200100063T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (2) TWI283579B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO1999063973A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA200007299B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1879630A (zh) * 1998-06-11 2006-12-20 内部研究股份有限公司 雄－5－烯－3β,17β－二醇的药物组合物及其用途
US6465445B1 (en) 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US6667299B1 (en) * 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
US20060079492A1 (en) * 1999-10-25 2006-04-13 Ahlem Clarence N Compositions and treatment methods
WO2000076522A1 (en) 1999-06-11 2000-12-21 Watson Pharmaceuticals, Inc. Administration of non-oral androgenic steroids to women
RU2327461C2 (ru) 1999-07-06 2008-06-27 Андорешерш, Инк. Способы лечения и/или подавления прироста массы
ATE501722T1 (de) 1999-09-30 2011-04-15 Harbor Biosciences Inc Therapeutische behandlung androgenrezeptorbedingter leiden
AU7896100A (en) * 1999-10-14 2001-04-23 Endorecherche Inc. Selective estrogen receptor modulators in the treatment or reduction of the riskof acquiring hypertension, cardiovascular diseases, and insulin resistance
FR2803750B1 (fr) * 2000-01-17 2004-04-02 Assist Publ Hopitaux De Paris Utilisation par voie orale de la dehydroepiandrosterone, de ses precurseurs biologiques et de ses derives metaboliques comme anti-atrophiant
WO2001062259A1 (en) * 2000-02-25 2001-08-30 Hollis Eden Pharmaceuticals Method of treatment of prostate cancer
DE10039199A1 (de) * 2000-08-10 2002-02-21 Schering Ag Kombinationspräparate aus einem ERß selektiven Estrogen und einem SERM oder Antiestrogen
FR2825277B1 (fr) * 2001-05-30 2004-10-15 Oreal Composition cosmetique et/ou dermatologique et/ou pharmaceutique contenant au moins un compose ihnibiteur de l'enzime 3, b-hsd
DE10151363A1 (de) * 2001-10-17 2003-05-08 Schering Ag Somatotrope Therapie
WO2003070253A1 (en) * 2002-02-21 2003-08-28 Pantarhei Bioscience B.V. Estrogenic component for treating decreased libido in women
AU2003224561A1 (en) * 2002-04-23 2003-11-10 Sahltech I Goteborg Ab Use of dhea for treatment of female hypopituitarism
US20050101581A1 (en) * 2002-08-28 2005-05-12 Reading Christopher L. Therapeutic treatment methods 2
AU2003278744B2 (en) * 2002-08-28 2010-07-29 Harbor Biosciences, Inc. Therapeutic treatment methods
GB0302572D0 (en) 2003-02-05 2003-03-12 Astrazeneca Ab Method of treatment
CA2574766A1 (en) * 2004-06-23 2006-01-26 Merck & Co., Inc. Estrogen receptor modulators
CA2584524C (en) * 2004-10-20 2012-02-07 Endorecherche, Inc. Sex steroid precursors alone or in combination with a selective estrogen receptor modulator and/or with estrogens and/or a type 5 cgmp phosphodiesterase inhibitor for the prevention and treatment of vaginal dryness and sexual dysfunction in postmenopausal women
CN101094676A (zh) * 2004-11-01 2007-12-26 恩多研究公司 雄激素在降低获得皮肤老化的可能性或治疗皮肤老化中的应用
EP1967202A1 (en) * 2007-03-05 2008-09-10 AEterna Zentaris GmbH Use of LHRH Antagonists for the Treatment of Lower Urinary Tract Symptoms, in particular Overactive Bladder and/or Detrusor Overactivity
US8268806B2 (en) 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions
WO2009026473A2 (en) * 2007-08-21 2009-02-26 Hollis-Eden Pharmaceuticals, Inc. Stabilized therapeutic compositions and formulations
EP2053055A1 (de) * 2007-10-24 2009-04-29 Bayer Schering Pharma Aktiengesellschaft 11.beta.-Fluoro-3-acetoxyestra-3,5-dien-17-on und Verfahren zu seiner Herstellung
JP2010109894A (ja) * 2008-10-31 2010-05-13 Fujitsu Ltd 弾性波フィルタ、デュープレクサ、通信モジュール、および通信装置
US20100317635A1 (en) * 2009-06-16 2010-12-16 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
AU2014201406B2 (en) * 2009-06-16 2016-08-11 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
KR20190042762A (ko) 2010-06-16 2019-04-24 앙도르쉐르슈 인코포레이티드 에스트로겐-관련 질병의 치료 또는 예방 방법
US20130178747A1 (en) * 2012-01-10 2013-07-11 Peter J. Muran Breast cancer precursor evaluation system and proactive breast wellness program
CN105037532B (zh) * 2015-07-27 2018-02-09 苏州博源医疗科技有限公司 17‑酮类固醇免疫原、抗体和检测试剂及制备方法
CN111830169B (zh) * 2020-07-24 2022-07-12 中山大学 多囊卵巢综合征诊断的化合物及应用

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US424954A (en) * 1890-04-08 Table-knife
US279982A (en) * 1883-06-26 Thomas beid
US816689A (en) * 1904-07-07 1906-04-03 Charles M Stevenson Merry-go-round.
CH203260A (de) 1936-11-24 1939-02-28 Dreiding Boris Mittel zur örtlichen Erzeugung von Wärme.
US2185187A (en) * 1938-05-23 1940-01-02 Vlieg Gerard A De Rotary cutter
FR672M (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1960-08-31 1961-07-17
US3797444A (en) 1971-04-19 1974-03-19 H Stubbs Towing guide
US3742951A (en) 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
US4139617A (en) * 1974-05-13 1979-02-13 Richardson-Merrell Inc. 19-Oxygenated-androst-5-enes for the enhancement of libido
US4040401A (en) 1974-11-05 1977-08-09 Ethyl Corporation Spark vacuum advance control
US4064654A (en) 1975-03-20 1977-12-27 H. G. Olson & Co., Inc. Sealed closures with weather stripping
JPS53144014A (en) 1977-05-20 1978-12-15 Masaya Koyama Automatic sprayer
DE3333240A1 (de) 1983-09-12 1985-03-28 Schering AG, 1000 Berlin und 4709 Bergkamen Mittel zur transdermalen applikation von arzneimittelwirkstoffen
US4634694A (en) 1984-01-14 1987-01-06 Akzo N.V. Novel Δ4 - and Δ5 -androstene derivatives and pharmaceutical compositions containing these derivatives
US4725439A (en) 1984-06-29 1988-02-16 Alza Corporation Transdermal drug delivery device
US4624665A (en) 1984-10-01 1986-11-25 Biotek, Inc. Method of transdermal drug delivery
US4568343A (en) 1984-10-09 1986-02-04 Alza Corporation Skin permeation enhancer compositions
US5155045A (en) * 1985-01-25 1992-10-13 Trustees Of The University Of Penn. Use of male essence to alter female endocrine response
US4666441A (en) 1985-12-17 1987-05-19 Ciba-Geigy Corporation Multicompartmentalized transdermal patches
IE60941B1 (en) 1986-07-10 1994-09-07 Elan Transdermal Ltd Transdermal drug delivery device
US4816258A (en) 1987-02-26 1989-03-28 Alza Corporation Transdermal contraceptive formulations
US5887216A (en) * 1997-03-19 1999-03-23 Ricoh Company, Ltd. Method and system to diagnos a business office device based on operating parameters set by a user
US5686465A (en) * 1988-10-31 1997-11-11 Endorecherche Inc. Sex steroid activity inhibitors
CA2004203A1 (en) 1988-12-01 1990-06-01 Sharad K. Govil Compositions for transdermal delivery of estradiol
US5461042A (en) * 1988-12-30 1995-10-24 Loria; Roger M. Regulation of the immune system
JP2959839B2 (ja) * 1989-07-07 1999-10-06 アンドルシェルシュ・インコーポレイテッド 性ステロイド活性の抑制における使用のためのアンドロゲン誘導体
US5116828A (en) * 1989-10-26 1992-05-26 Nippon Zoki Pharmaceutical Co., Ltd. Pharmaceutical composition for treatment of osteoporosis
US5641768A (en) * 1989-11-17 1997-06-24 Loria; Roger M. 5-androstene 3β, 17β diol for treatment
US5071644A (en) 1990-08-07 1991-12-10 Mediventures, Inc. Topical drug delivery with thermo-irreversible gels
US5424463A (en) * 1990-08-29 1995-06-13 Humanetics Corporation Δ5-androstenes useful for promoting weight maintenance or weight loss and treatment process
US5183815A (en) * 1991-01-22 1993-02-02 Merck & Co., Inc. Bone acting agents
US5206008A (en) * 1991-04-15 1993-04-27 Virginia Commonwealth University Enhancement of immune response
ZA924811B (en) * 1991-06-28 1993-12-29 Endorecherche Inc Controlled release systems and low dose androgens
ES2146228T3 (es) * 1992-02-24 2000-08-01 Univ East Carolina Metodo para inhibir la carcinogenesis mediante tratamiento con deshidro-epiandrosterona y sus analogos.
FR2696934B1 (fr) * 1992-10-20 1995-06-02 Conservatoire Nal Arts Metiers Dérivés de stéroïdes naturels 3B hydroxyles ayant des propriétés de déclenchement et de stimulation de l'immunité, composition les contenant et procédé pour les obtenir.
DK0680327T3 (da) 1993-01-19 2005-01-03 Endorech Inc Terapeutiske anvendelser af og leveringssystemer for dehydroepiandrosteron
US5776923A (en) 1993-01-19 1998-07-07 Endorecherche, Inc. Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone
US5387583A (en) * 1993-04-20 1995-02-07 Loria; Roger M. Compositions containing corticosteroids or analogues thereof and corticosteroid buffering effective amounts of 5-androstene 3B, 17B or 5-androstene 3B, 7B, 17B triol or analogues thereof
US5571933A (en) * 1994-11-17 1996-11-05 Duquesne University Of The Holy Ghost Derivatives of estra 1,3,5(10)triene-17-one, 3-amino compounds and their use
ES2098193B1 (es) * 1995-07-21 1997-12-01 Gomez Jesus Calderon Nueva formulacion farmaceutica de dehidroepiandrosterona para aplicacion topica percutanea.
US5828688A (en) * 1995-10-26 1998-10-27 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Method and apparatus for linewidth reduction in distributed feedback or distributed bragg reflector semiconductor lasers using vertical emission
US6653331B2 (en) * 1996-07-03 2003-11-25 Pharmacia & Upjohn Company Targeted drug delivery using sulfonamide derivatives
US5770226A (en) * 1996-07-10 1998-06-23 Wake Forest University Combined pharmaceutical estrogen-androgen-progestin oral contraceptive
US6139873A (en) * 1996-07-10 2000-10-31 Cedars-Sinai Medical Center Combined pharmaceutical estrogen-androgen-progestin
IT1292129B1 (it) * 1997-06-11 1999-01-25 Sunnimex Ltd Medicamento utile per ridurre la massa grassa ed aumentare la massa magra nella donna in menopausa ed in entrambi i sessi nella
WO1999007381A1 (en) * 1997-08-11 1999-02-18 Weider Nutrition International, Inc. Compositions and treatments to reduce side effects of administration of androgenic testosterone precursors
JP2001520999A (ja) * 1997-10-28 2001-11-06 アシビ， エルエルシー 女性の性的機能不全の処置
US5877216A (en) * 1997-10-28 1999-03-02 Vivus, Incorporated Treatment of female sexual dysfunction
CN1879630A (zh) * 1998-06-11 2006-12-20 内部研究股份有限公司 雄－5－烯－3β,17β－二醇的药物组合物及其用途
US6703381B1 (en) * 1998-08-14 2004-03-09 Nobex Corporation Methods for delivery therapeutic compounds across the blood-brain barrier
US6117446A (en) * 1999-01-26 2000-09-12 Place; Virgil A. Drug dosage unit for buccal administration of steroidal active agents
US6284262B1 (en) * 1999-01-26 2001-09-04 Virgil A. Place Compact dosage unit for buccal administration of a pharmacologically active agent
RU2327461C2 (ru) * 1999-07-06 2008-06-27 Андорешерш, Инк. Способы лечения и/или подавления прироста массы
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20020107230A1 (en) * 2000-12-22 2002-08-08 Waldon R. Forrest Methods and formulations for the treatment of female sexual dysfunction
EP1390038A2 (en) * 2001-05-16 2004-02-25 Endeavor Pharmaceuticals Treatment of conditions relating to hormone deficiencies by administration of progestins

Also Published As

Publication number Publication date
US20020187963A1 (en) 2002-12-12
US6995150B2 (en) 2006-02-07
ZA200007299B (en) 2002-04-24
KR20060098400A (ko) 2006-09-18
US20020187969A1 (en) 2002-12-12
TR200102867T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2002-06-21
KR100679735B1 (ko) 2007-02-07
TR200100063T2 (tr) 2001-05-21
CA2334702C (en) 2005-10-18
HK1037329A1 (en) 2002-02-08
KR20060098399A (ko) 2006-09-18
US20020187962A1 (en) 2002-12-12
US20080161277A1 (en) 2008-07-03
MY131522A (en) 2007-08-30
TWI263499B (en) 2006-10-11
HUP0102483A2 (hu) 2001-11-28
US20020187967A1 (en) 2002-12-12
US20020187964A1 (en) 2002-12-12
US20020187966A1 (en) 2002-12-12
US6884795B2 (en) 2005-04-26
CA2334702A1 (en) 1999-12-16
KR20010052764A (ko) 2001-06-25
IL175723A0 (en) 2006-09-05
PL345955A1 (en) 2002-01-14
CN1626095A (zh) 2005-06-15
EP1083904A2 (en) 2001-03-21
US20020187965A1 (en) 2002-12-12
NO20006286D0 (no) 2000-12-11
WO1999063973A3 (en) 2000-11-02
ID27922A (id) 2001-05-03
HUP0102483A3 (en) 2002-11-28
JP2002517432A (ja) 2002-06-18
CN100377711C (zh) 2008-04-02
TWI283579B (en) 2007-07-11
NZ536787A (en) 2006-03-31
AR018660A1 (es) 2001-11-28
MXPA00012304A (es) 2003-05-15
CN1243550C (zh) 2006-03-01
NO20006286L (no) 2001-01-31
WO1999063973A2 (en) 1999-12-16
TW200630101A (en) 2006-09-01
IL140225A0 (en) 2002-02-10
CN1311682A (zh) 2001-09-05
RU2221569C2 (ru) 2004-01-20
US20020187970A1 (en) 2002-12-12
US6432940B1 (en) 2002-08-13
CN1879630A (zh) 2006-12-20
AU4127499A (en) 1999-12-30
HK1078004A1 (en) 2006-03-03
US20020187973A1 (en) 2002-12-12
US20020187968A1 (en) 2002-12-12
EP1731157A2 (en) 2006-12-13
US6964955B2 (en) 2005-11-15
EP1731157A3 (en) 2009-07-15

Similar Documents

Publication Publication Date Title
BR9911115A (pt) Composições farmacêuticas e usos para oandrost-5-eno-3 beta, 17 beta-diol
Regidor Progesterone in peri-and postmenopause: a review
Halbreich et al. Are there differential symptom profiles that improve in response to different pharmacological treatments of premenstrual syndrome/premenstrual dysphoric disorder?
PT748190E (pt) Metodos e formulacoes para uso no tratamento de disturbios ginecologicos benignos
US20080167274A1 (en) Composition containing progestin, phytoestrogen and vitamin d
Kloosterboer et al. Pros and cons of existing treatment modalities in osteoporosis: a comparison between tibolone, SERMs and estrogen (±progestogen) treatments
Davis et al. Postmenopausal hormone therapy: from monkey glands to transdermal patches
ES2176190T3 (es) Inhibidores de la actividad de esteroides sexuales.
BRPI0411295A (pt) compostos e seu uso na terapia
WO2006053172A3 (en) The use of estriol and other estranes, estrogens and estrogen receptor active compositions in the treatment of psoriasis and other autoimmune diseases
BRPI0416275A (pt) métodos de tratar, controlar ou prevenir um cáncer especìfico e uma doença associada com angiogênese indesejada
Egarter et al. Efficacy, tolerability, and rare side effects of tibolone treatment in postmenopausal women
ES2180690T3 (es) Preparacion de composiciones que comprenden st1435 para aplicacion topica.
BR0008076A (pt) 16-hidroxiestratrienos como estrogênios de efeito seletivo
Levedahl et al. Metabolism of testosterone and 17-methyltestosterone by liver tissue
Zingue et al. Lupeol, the major compound of the dichloromethane extract of Millettia macrophylla Benth (Fabaceae), displays estrogenic effects in ovariectomized rats
Freeman et al. Estrogen sulfotransferase activity in guinea pig uterus and chorion
WO2002053137A3 (en) Pharmaceutical composition for treatment of phimosis using topical corticosteroid
Suhana Mohd Ramli et al. Piper sarmentosum: a new hope for the treatment of osteoporosis
Cameron et al. Vaginal spermicidal activity of gossypol in the Macaca arctoides
ATE286739T1 (de) Verwendung einer pollenextrakt-haltigen verbindung zur behandlung erkrankungsbedingter gewichtszunahme
Rozenberg et al. Constant estrogen, intermittent progestogen vs. continuous combined hormone replacement therapy: tolerability and effect on vasomotor symptoms
DE69525181D1 (de) Tnf-rezeptor und steroidhormon dhea in einer kombinationstherapie
Wang et al. Effects of tibolone on the breast of postmenopausal women
Van Den Koedijk et al. Comparative affinity of steroidal and non-steroidal antioestrogens, cholesterol derivatives and compounds with a dialkylamino side chain for the rat liver antioestrogen binding site

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 4A ANUIDADE.

B08G Application fees: restoration [chapter 8.7 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DA INT.CL: A61K 31/565, A61P 5/30, A61P 15/12, A61P 15/02, A61P 15/08, A61P 19/10, A61P 35/00, A61P 3/04, A61P 3/10, A61P 25/28

Ipc: A61K 31/00 (2009.01)

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFERIDO O PEDIDO COM BASE NOS ARTIGOS 8O, 11 E 13 DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.